Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy

Version 1 : Received: 9 September 2021 / Approved: 13 September 2021 / Online: 13 September 2021 (12:36:12 CEST)

How to cite: Quazi, S. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy. Preprints 2021, 2021090212 (doi: 10.20944/preprints202109.0212.v1). Quazi, S. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy. Preprints 2021, 2021090212 (doi: 10.20944/preprints202109.0212.v1).

Abstract

Multiple Myeloma (MM) is one of the incurable types of cancer in plasma cells. While immense progress has been made in the treatment of this malignancy, a large percentage of patients were unable to adapt to such therapy. Additionally, these therapies might be associated with significant diseases and are not always tolerated well in all patients. Since cancer in plasma cells has no cure, patients develop resistance to treatments, resulting in R/R MM. BCMA is primarily produced on mature B cells. Its up-regulation and activation are associated with multiple myeloma in both murine and human models, indicating that this might be an effective therapeutic target for this type of malignancy. Additionally, BCMA's predictive value, association with effective clinical trials, and capacity to be utilized in previously difficult to observe patient populations, imply that it might be used as a biomarker for multiple myeloma. Numerous kinds of BCMA-targeting medicines have demonstrated antimyeloma efficacy in individuals with refractory/relapsed MM, including CAR T-cell treatments, ADCs, bispecific antibody constructs. Among these medications, CART cell-mediated BCMA therapy has shown significant outcomes in multiple myeloma clinical trials. This review article outlines CAR T cell mediated BCMA medicines have the efficiency to change the therapeutic pattern for multiple myeloma significantly.

Keywords

BCMA; CAR T cell; Multiple Myeloma; Refractory/Relapsed; ADCs; Bispecific Antibody

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.